Hipreb-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Rabeprazole 20 mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by accelerating gastric emptying and improving esophageal sphincter tone, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related conditions. The synergistic action of Domperidone and Rabeprazole in Hipreb-DSR Capsule provides comprehensive symptomatic relief by addressing both motility dysfunction and acid hypersecretion. This combination is particularly beneficial in patients with GERD who experience delayed gastric emptying or associated motility disturbances. Hipreb-DSR should be administered as prescribed by a healthcare professional, with consideration given to patient-specific factors such as existing comorbidities and concomitant medications. Caution is advised in patients with cardiac arrhythmias or prolonged QT interval due to Domperidone’s potential cardiac effects. Overall, Hipreb-DSR Capsule offers a targeted therapeutic approach for improved gastrointestinal function and symptom control.